Umpqua Bank Invests $263,000 in Pfizer Inc. (NYSE:PFE)

Umpqua Bank acquired a new position in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,943 shares of the biopharmaceutical company’s stock, valued at approximately $263,000.

A number of other hedge funds have also bought and sold shares of PFE. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer in the 4th quarter valued at $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the fourth quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer during the 4th quarter worth about $28,000. Noble Wealth Management PBC acquired a new stake in shares of Pfizer in the 4th quarter valued at about $31,000. Finally, Curio Wealth LLC bought a new stake in Pfizer in the 4th quarter valued at about $32,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.1 %

Shares of NYSE:PFE opened at $26.20 on Friday. The business has a fifty day moving average price of $26.17 and a two-hundred day moving average price of $27.04. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a market capitalization of $148.61 billion, a PE ratio of 18.58, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the previous year, the firm posted $0.10 EPS. Pfizer’s revenue was up 24.7% on a year-over-year basis. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on PFE. Bank of America reissued a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup reduced their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.